Title: Moderna Develops One-Dose Vaccine for COVID-19 and Influenza

Moderna is developing a single-dose vaccine that it believes will be effective against COVID-19 and influenza. Darius Hughes, the head of the American pharmaceutical company in the UK, predicts that the new vaccine will be ready by early next year. The British newspaper Daily Mail reported Hughes as saying, "The annual combination vaccine will be more convenient for patients as it requires fewer visits to medical facilities, and it will also reduce the cost of vaccination management borne by the UK National Health Service." Hughes added, "Vaccination against COVID-19 and influenza may be available by winter 2023." He continued, "It is fantastic for patients to receive a vaccine that protects against all respiratory diseases at once." Moderna is also working on a vaccine to combat the rapidly spreading Omicron variant, with early-stage efficacy data expected to emerge in the next two weeks. According to the latest Reuters tally, more than 301.83 million people worldwide have contracted the coronavirus, while the total number of deaths attributed to the virus has reached 5,828,343. Infections have been recorded in more than 210 countries and regions since the first cases were discovered in China in December 2019.